$599

Zealand and Madrigal Q4 ’25 Earnings; Novo Initiates Ph2 T2DM Study of Internal Triple-Agonist; Goodpath Expands Wegovy Access

A series of cardiometabolic-related news items has been observed from Zealand Pharma, Novo Nordisk, Madrigal Pharmaceuticals, and Goodpath. Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here